Clinicopathological Significance of MTA 1 Expression in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis.
Clinicopathological Significance of MTA 1 Expression in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis.
复制标题
非小细胞肺癌患者 MTA 1 表达的临床病理意义：荟萃分析
DOI：
10.22034/apjcp.2017.18.11.2903
复制
发表时间：
2017-11-26
期刊：
影响因子：
--
通讯作者：
Wang X
中科院分区：
文献类型：
--
作者：
Zhu W;Li G;Guo H;Chen H;Xu X;Long J;Zeng C;Wang X
背景：转移相关基因1(MTA1)是人类肿瘤中表达最多的分子之一，与肿瘤的进展和转移密切相关。我们进行了Meta分析，以确定MTA1的表达与非小细胞肺癌(NSCLC)临床病理特征的相关性。方法：应用计算机检索PubMed、Springer、Science Direct、Google Scholar和中国期刊全文数据库中国的相关文章。统计分析采用R3.1.1软件。根据同质性统计检验的结果，采用固定或随机效应模型。结果：共纳入7项研究，涉及660名非小细胞肺癌患者。其95%可信区间(95%CI)分别为0.53(95%CI：0.43~0.62)、0.47(95%CI：0.40~0.55)和0.52(95%CI：0.34~0.70)，男性为0.5(95%CI：0.41~0.62)，女性为0.51(95%CI：0.39~0.62)；≥患者MTA1过度表达的95%可信区间(95%CI)为0.53(95%CI：0.43~0.62)；鳞癌0.59(95%CI：0.48~0.69)，腺癌0.57(95%CI：0.46~0.67)，高分化肿瘤0.39(95%CI：0.23~0.56)，中分化肿瘤0.44(95%CI：0.37~0.51)，低分化肿瘤0.55(95%CI：0.37~0.51)；NSCLC临床分级(III~IV级)为0.48(95%CI：0.36~0.60)，临床分级(I~II级)为0.75(95%CI：0.69~0.81)，T期(T1/T2)为0.58(95%CI：0.45~0.71)，淋巴结阳性组为0.68(95%CI：0.49~0.82)，淋巴结阴性组为0.51(95%CI：0.43~0.58)。结论：MTA1在非小细胞肺癌的诊断中可能是一个有价值的生物标志物。MTA1的过度表达与≥患者的年龄、性别、组织学类型、临床分级(I-II)、T分期(T1/T2)和淋巴结阳性有关。
Background: Metastasis associated gene 1(MTA1) is one of the most deregulated molecules in human cancer and leads to cancer progression and metastasis. We performed a meta-analysis to determine the correlations between MTA1 expression and the clinicopathological characteristics of non-small cell lung cancer (NSCLC). Methods: We searched PubMed, Springer, Science Direct, Google Scholar and China National Knowledge Infrastructure (CNKI) for relevant articles. For statistical analyses, we used R3.1.1 software. The fixed or random effects model was employed based on the results of the statistical test for homogeneity. Results: Seven studies involving 660 NSCLC patients were included. The proportion of MTA1 overexpression with 95% confidence interval (95% CI) was 0.53(95% CI: 0.43-0.62) in NSCLC patients; 0.47(95% CI: 0.40-0.55) in age <60 years and 0.52(95% CI: 0.34-0.70) in age ≥60 years; 0.5(95% CI: 0.41-0.62) in males and 0.51(95% CI: 0.39-0.62) in females; 0.59(95% CI: 0.48-0.69) in squamous cell carcinoma (SC) and 0.57(95% CI: 0.46-0.67) in adenocarcinoma (AC); 0.39(95% CI: 0.23-0.56) in well-differentiated tumors, 0.44(95% CI: 0.37-0.51) in moderately differentiated tumors and 0.55(95% CI: 0.37-0.51) in poorly differentiated tumors; 0.48(95% CI: 0.36-0.60) in clinical grade (III-IV) NSCLC and 0.75 (95% CI: 0.69-0.81) in clinical grade (I-II) NSCLC; 0.58(95% CI: 0.45-0.71) in T Stage (T1/T2) NSCLC; 0.68(95% CI: 0.49-0.82) in NSCLC patients with lymph node positivity and 0.51(95% CI: 0.43-0.58) in NSCLC patients with lymph node negativity. Conclusions: These results indicated that MTA1 might be a valuable biomarker in the diagnosis of NSCLC. MTA1 overexpression was significantly associated with age ≥60 years, gender, histopathological type, clinical grade (I-II), T stage (T1/T2) and lymph node positivity in NSCLC patients.